As their motto states, “Good Health Can’t Wait,” Dr Reddy’s Laboratories ensures essential medicines are available for all. You might remember Nise/ Nimesuldie, the go-to medication for fever or body pain loved by our families. Dr Kallam Anji Reddy, the founder and owner of Dr. Reddy’s laboratories, had a profound passion for drug discovery.
His journey began in Tadepalli village, Andhra Pradesh, India. He grew up in a farming family known for freely distributing herbal pills to those in need. It was during this time that the seeds for Dr. Reddy’s Laboratories’ history were sown. His early exposure to medicine and community service deeply influenced him.
Today, Dr. Reddy’s Lab serves needs in gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology.
Let’s explore the history of Dr. Reddy’s Laboratories today.
Dr. Reddy’s Laboratories Company Profile
| Feature | Details |
| Founded | 1984 |
| Founder | Dr Kallam Anji Reddy |
| Chairman | Satish Reddy, G V Prasad (Co-Chairman and MD) |
| Headquarters | Hyderabad, India |
| Market Cap | ₹ 99,438 Cr. |
| Revenue | Rs. 72,148 Cr (Q3FY24) |
| Products | Over 200 products, including Generics, Branded Generics, Biosimilars, and Over-the-Counter Pharmaceutical Products for gastroenterology, oncology, pain management, cardiovascular, etc. |
| Rank in India | 5th based on Market Cap (As of June 20th, 2024) |
| Locations | Over 25 countries, including Romania, Russia, South Africa, Spain, Ukraine, the United Kingdom, the United States, etc. |
Source- Drreddys.com/,screener.in,data, as of June 20th, 2024.
History of Dr. Reddy’s Laboratories
In 1985, a small yet ambitious API factory opened its doors in Bollaram, Hyderabad.
It was the beginning of Dr Reddy’s journey in the field of pharmaceuticals.
The following year, 1986, marked a significant milestone as Dr Reddy’s went public and became listed on the Bombay Stock Exchange.
They proudly introduced APIs for the first time in India.
Was this all?
Not at all!
Dr Reddy’s Laboratories quickly became pioneers by exporting APIs to the USA.
Fast forward to 1991, the company launched Omez (Omeprazole) for heartburn and gastro-related problems.
It became a household name in India.
In 1992, Dr Reddy’s expanded its global footprint by establishing a branch in Russia.
In 1993, their commitment to innovation deepened with the initiation of new drug discovery through the Dr. Reddy’s Research Foundation.
They were indeed setting the stage for future advancements.
By 1996, Dr. Anji Reddy, the visionary founder, established the Dr. Reddy’s Foundation (DRF).
Its aim?
The foundation wanted to give back to society through health, education, livelihood, and environmental initiatives.
The year 1997 marked another milestone as Dr. Reddy’s became the first Indian pharma company to out-license a novel drug.
In 2001, Dr Reddy’s achieved remarkable feats:
- Listing on the New York Stock Exchange
- Obtaining exclusive rights from the USFDA for Fluoxetine capsules
- Received the prestigious Padma Shri for Dr. Anji Rdeddy’s contributions.
What more?
They also pioneered ‘Self-Managed Teams’ to empower youth around their manufacturing sites.
The following year, 2002, saw the inception of Aurigene Discovery Technologies Ltd, a subsidiary focused on new drug discovery. This was based in Bengaluru.
In 2003, Dr. Reddy’s Laboratories’ commitment to sustainability and transparency was evident with the release of its first Safety, Health, Environment (SHE) report and annual sustainability disclosures.
By 2006, the company had become the fastest Indian pharma company to surpass USD 1 billion in revenue. It also launched the first Authorized Generic (AG) in the U.S.
In 2007, Dr. Reddy’s Lab introduced Reditux. It was the world’s first monoclonal antibody biosimilar of rituximab.
In 2010, Dr. Reddy’s continued to innovate with the launch of Cresp, the world’s first generic darbepoetin alfa in India.
The year 2011 brought further accolades as Dr Anji Reddy received the Padma Bhushan for his contributions to the Indian pharma industry.
By 2016, the company expanded into the branded consumer health sector and earned a spot on the Dow Jones Sustainability Index for Emerging Markets.
In 2019, they ventured into nutrition and nutraceuticals in India!
The year 2020 was pivotal as Dr Reddy joined the Science-Based Targets initiative. They made significant strides in fighting COVID-19 with vaccines and therapeutics, reaching millions worldwide.
In 2022, recognition continued with Dr Reddy’s Foundation receiving a National Award and their Hyderabad facility being honoured by the World Economic Forum.
They refreshed their ESG goals and were named among the Top 20 employers globally in pharma/biotech.
In 2023, Dr Reddy’s achieved more milestones:
- Their debut on the Dow Jones Sustainability World Index
- Launched Nerivio® for migraine management
- Expanded into digital therapeutics and e-commerce in India.
As they celebrated #40YearsOfDrReddys in 2024, Dr Reddy continues to innovate and lead!
Nestlé India and Dr Reddy’s Laboratories Collaboration 2024
In April 2024, Nestlé India and Dr Reddy’s Labs joined forces to create a new partnership. They formed a joint venture to bring advanced health products to people in India and other regions.
Nestlé Health Science and Dr Reddy’s Laboratories aim to expand their offerings in metabolic health and hospital nutrition.
This initiative is a big step forward in providing better health options for everyone.
Dr. Reddy’s Laboratories Company Profile
Established in 1984, Dr Reddy’s Laboratories Ltd. is dedicated to ensuring affordable medicines globally. It has a presence in over 25 countries and a portfolio of over 200 products. The World Economic Forum celebrates Dr Reddy Labs for its cutting-edge Hyderabad facility.
- Chairman of Dr. Reddy’s Laboratories: Satish Reddy
- Founder of Dr. Reddy’s Laboratories: Dr. Kallam Anji Reddy.
- Dr Reddy’s Laboratories Headquarters: Hyderabad
- Dr Reddy’s Laboratories Products-
It produces a wide range of healthcare products worldwide, including:
- Active Pharmaceutical Ingredients (API)
- Generics
- Branded generics
- Biosimilars
- Over-the-counter pharmaceuticals.
They specialize in gastroenterology, cardiovascular health, diabetology, oncology, pain management, and dermatology.
- Dr. Reddy’s Laboratories Rank in India
Currently ranks 5th in India based on Market Cap as of June 20th, 2024.
- Dr. Reddy’s Laboratories Headquarters: Located in Hyderabad, India.
- Dr. Reddy’s Laboratories Market Cap: ₹ 99,438 Cr.
- Dr. Reddy’s Laboratories Revenue: Rs. 72,148 Mn in Q3FY24.
- Dr. Reddy’s Laboratories Locations
It has business operations in over 25 countries, including Romania, Russia, South Africa, Spain, Ukraine, the United Kingdom, the United States, and more.
You may also want to know the Ipca Laboratories Limited
Dr. Reddy’s Laboratories’ Commitment to Sustainability
Dr. Reddy’s Laboratories aims to make a positive impact on the environment and society.
These goals include:
- Committing to environmental stewardship
- Ensuring accessibility and affordability of their products to patients
- Contributing to a fairer and more socially inclusive world
- Enhancing trust with stakeholders
- Reducing carbon emissions.
To achieve these objectives, Dr. Reddy’s Laboratories has set specific targets:
- Transitioning to 100% renewable power by 2030,
- Achieving carbon neutrality in their direct operations (Scope 1 and Scope 2 emissions) by 2030,
- Cutting indirect carbon emissions across their supply chain (Scope 3 emissions) by 12.5% by 2030.
- Additionally, Dr. Reddy’s aims to become water-positive by 2025.
The Purple Health initiative in India aims to enhance patient care beyond medication, focusing on four areas:
increasing disease awareness and providing convenient diagnosis, ensuring access to medicines, improving the therapy experience, and promoting adherence to therapy.
FAQs| Dr. Reddy’s Laboratories History
Yes, Dr. Reddy’s Laboratories is a multinational corporation (MNC) with operations in over 4 countries.
Dr. Reddy’s Laboratories is an Indian pharmaceutical company headquartered in Hyderabad, India.
As of June 20th, based on market cap, Dr. Reddy’s Laboratories holds the 5th rank.
Dr. Reddy’s Laboratories merged with Nestlé India to bring nutraceutical brands to consumers in India and other agreed territories.
______________________________________________________________________________________
Disclaimer: Investments in the securities market are subject to market risks; read all the related documents carefully before investing.